EA
ENTA icon

Emerald Acquisition’s Enanta Pharmaceuticals ENTA Stock Holding History

Emerald Acquisition’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		$1.16M Sell
43,411
-66,336
-60% -$1.54M ﹤0.01% 2049
2016
Q2 		$2.42M Buy
+109,747
New +$2.87M ﹤0.01% 1731

Other funds holding ENTA

BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SAM
Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AL
AJO LP Philadelphia, Pennsylvania $199M AUM 109.68% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Emerald Acquisition's ENTA Position: Q3 2016 in Review

Emerald Acquisition reduced its Enanta Pharmaceuticals (ENTA) stake by 60% in Q3 2016, selling an estimated $1.54M and leaving 43,411 shares worth $1.16M. The position accounts for ﹤0.01% of the portfolio, ranked #2049.

Emerald Acquisition first reported a position in ENTA in Q2 2016 and has held it in 2 quarters since. The position peaked at $2.42M in Q2 2016. 136 funds tracked by Wall St. Rank hold ENTA as of Q3 2016.

  • Emerald Acquisition held 43,411 shares of Enanta Pharmaceuticals worth $1.16M as of Q3 2016.
  • Emerald Acquisition sold 66,336 Enanta Pharmaceuticals shares in Q3 2016, an estimated $1.54M.
  • Enanta Pharmaceuticals made up ﹤0.01% of Emerald Acquisition's portfolio in Q3 2016, its #2049 holding.
  • Emerald Acquisition first reported a position in Enanta Pharmaceuticals in Q2 2016 and has held it in 2 quarters since.
  • Emerald Acquisition's Enanta Pharmaceuticals position peaked at $2.42M in Q2 2016.
  • 136 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q3 2016.

Based on Emerald Acquisition's 13F filing for Q3 2016, filed 9 Nov 2016.